Mavyret 40 mg/1

Mavyret 40 mg/1 is a combination of glecaprevir and pibrentasvir, used for treating certain types of hepatitis C. This oral medication is designed to target the virus and support liver health.

Mavyret 40 mg/1 is primarily used for the treatment of chronic hepatitis C virus (HCV) infection. It is often prescribed for adults with specific genotypes of HCV, either with or without cirrhosis. The medication works by targeting the virus directly, aiming to reduce its presence in the body. Patients should consult their healthcare provider to determine if Mavyret is suitable for their specific condition.

Common effects of Mavyret 40 mg/1 may include fatigue, headache, and nausea. Some individuals might experience changes in liver function tests. It is important to monitor for any unusual symptoms and report them to a healthcare professional.

Mavyret 40 mg/1 should be used with caution in patients with liver disease or those taking other medications. It is essential to follow the prescribed dosage and administration instructions. Pregnant women or those planning to become pregnant should discuss the potential risks with their healthcare provider.

Mavyret 40 mg/1 may interact with certain medications, including those metabolized by the liver enzymes CYP3A or CYP2C8. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol and other substances that affect liver function should be avoided.